hormonal therapy
Role of SPOP Mutations in Prostate, Endometrial Cancer Come Into Focus in Retrospective Analysis
Premium
Using Caris Life Sciences' database, researchers found that prostate and endometrial cancers with SPOP mutations have distinct immune characteristics.
Relay Therapeutics' Early Data on Selective PIK3Cα Inhibitor Suggest Promising Tolerability
At AACR, researchers presented preliminary data from the Phase I ReDiscover trial, which suggested RLY-2608 could have a better safety profile than Novartis' Piqray.
Adding Ibrance to Fulvestrant Doesn't Benefit CDK4/6 Inhibitor-Refractory Breast Cancer Patients
Premium
The PACE trial pitted Ibrance and fulvestrant against fulvestrant alone for HR-positive, HER2-negative breast cancer after CDK4/6 inhibitors plus endocrine therapy.
MD Anderson Study Explains Differing BRAF/MEK Treatment Responses in Male, Female Melanoma Patients
Premium
If validated, the findings could inform strategies for improving responses to BRAF/MEK inhibitors including using androgen receptor blockers.
NICE Recommends Eli Lilly's Verzenio as Adjuvant Treatment for High-Risk, Early-Stage Breast Cancer
The agency recommended the CDK4/6 inhibitor plus hormone therapy for HR-positive, HER2-negative, early-stage breast cancer patients at high risk of recurrence.